Active, Not Recruiting
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma, +18 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- Virginia G Piper Cancer Care-Del Camino Scottsdale, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States